Literature DB >> 33817237

Lnc-PICSAR contributes to cisplatin resistance by miR-485-5p/REV3L axis in cutaneous squamous cell carcinoma.

Dan Wang1, Xiaoqiang Zhou2, Jing Yin3, Yang Zhou4.   

Abstract

BACKGROUND: Dysregulation of long noncoding RNAs (lncRNAs) is associated with drug resistance in multiple cancers. We explored the roles of lncRNA p38 inhibited cutaneous squamous cell carcinoma-associated lincRNA (PICSAR) in cisplatin (DDP) resistance of cutaneous squamous cell carcinoma (CSCC).
METHODS: Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to measure the expression of lnc-PICSAR, miR-485-5p and reversionless 3-like (REV3L) mRNA. The cell counting kit-8 (CCK-8) assay was conducted to evaluate DDP resistance and cell viability. The transwell assay was performed to determine cell migration and invasion. Western blot assay and immunohistochemistry (IHC) staining assay were carried out to measure protein levels. The dual-luciferase reporter assay was used to investigate the association between miR-485-5p and lnc-PICSAR or REV3L. Murine xenograft model was constructed to explore the function of lnc-PICSAR in vivo. The morphology of exosomes was analyzed by transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA).
RESULTS: Lnc-PICSAR was elevated in DDP-resistant CSCC cells. Lnc-PICSAR silencing suppressed cell viability, DDP resistance, migration and invasion in DDP-resistant CSCC cells. MiR-485-5p acted as a target of lnc-PICSAR, and miR-485-5p inhibition reversed the impacts of lnc-PICSAR silencing on DDP resistance and cell progression in DDP-resistant CSCC cells. Lnc-PICSAR promoted REV3L expression via sponging miR-485-5p. Moreover, REV3L overexpression overturned the effects of lnc-PICSAR on cell progression and DDP resistance. Lnc-PICSAR knockdown suppressed DDP resistance in vivo. In addition, lnc-PICSAR was increased in the exosomes derived from CSCC patients' serum and CSCC cells.
CONCLUSION: Lnc-PICSAR enhanced DDP resistance via miR-485-5p/REV3L axis in DDP-resistant CSCC cells. Besides, exosome-mediated lnc-PICSAR might be involved in the regulation of drug resistance in CSCC.
© 2020 Dan Wang et al., published by De Gruyter.

Entities:  

Keywords:  CSCC; DDP resistance; REV3L; exosome; lnc-PICSAR; miR-485-5p

Year:  2020        PMID: 33817237      PMCID: PMC7874590          DOI: 10.1515/biol-2020-0049

Source DB:  PubMed          Journal:  Open Life Sci        ISSN: 2391-5412            Impact factor:   0.938


  31 in total

Review 1.  Cutaneous squamous-cell carcinoma.

Authors:  M Alam; D Ratner
Journal:  N Engl J Med       Date:  2001-03-29       Impact factor: 91.245

2.  MicroRNA-485-5p suppresses growth and metastasis in non-small cell lung cancer cells by targeting IGF2BP2.

Authors:  Ri-Sheng Huang; Yuan-Liang Zheng; Chang Li; Cheng Ding; Chun Xu; Jun Zhao
Journal:  Life Sci       Date:  2018-03-03       Impact factor: 5.037

3.  miR-145 Regulates the sensitivity of esophageal squamous cell carcinoma cells to 5-FU via targeting REV3L.

Authors:  Qing Chen; Juan Hou; Zhiwei Wu; Jie Zhao
Journal:  Pathol Res Pract       Date:  2019-04-28       Impact factor: 3.250

4.  lncRNA TINCR participates in ALA-PDT-induced apoptosis and autophagy in cutaneous squamous cell carcinoma.

Authors:  Wu Zhou; Shoumin Zhang; Jianguo Li; Zhenlu Li; Yuping Wang; Xueli Li
Journal:  J Cell Biochem       Date:  2019-04-16       Impact factor: 4.429

5.  PICSAR: Long Noncoding RNA in Cutaneous Squamous Cell Carcinoma.

Authors:  Yunhai Luo; Stefanie L Morgan; Kevin C Wang
Journal:  J Invest Dermatol       Date:  2016-08       Impact factor: 8.551

6.  Isolation and characterization of RNA-containing exosomes.

Authors:  Cecilia Lässer; Maria Eldh; Jan Lötvall
Journal:  J Vis Exp       Date:  2012-01-09       Impact factor: 1.355

7.  The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.

Authors:  Zhihua Li; Xiaohui Zhao; Yu Zhou; Yimin Liu; Quanbo Zhou; Huilin Ye; YinXue Wang; Jinlong Zeng; Yadong Song; Wenchao Gao; ShangYou Zheng; Baoxiong Zhuang; Huimou Chen; Wenzhu Li; Haigang Li; Haifeng Li; Zhiqiang Fu; Rufu Chen
Journal:  J Transl Med       Date:  2015-03-12       Impact factor: 5.531

8.  MicroRNA (miRNA) in cancer.

Authors:  Kaladhar B Reddy
Journal:  Cancer Cell Int       Date:  2015-04-02       Impact factor: 5.722

9.  hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma.

Authors:  Xiu-Juan Lin; Chang-Li He; Ting Sun; Xue-Jing Duan; Yi Sun; Shi-Jiang Xiong
Journal:  Int J Mol Med       Date:  2017-05-16       Impact factor: 4.101

10.  Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.

Authors:  Kie Kyon Huang; Kang Won Jang; Sangwoo Kim; Han Sang Kim; Sung-Moo Kim; Hyeong Ju Kwon; Hye Ryun Kim; Hwan Jung Yun; Myung Ju Ahn; Keon Uk Park; Kalpana Ramnarayanan; John R McPherson; Shenli Zhang; Je-Keun Rhee; André L Vettore; Kakoli Das; Takatsugu Ishimoto; Joo Hang Kim; Yoon Woo Koh; Se Hun Kim; Eun Chang Choi; Bin Tean Teh; Steven G Rozen; Tae-Min Kim; Patrick Tan; Byoung Chul Cho
Journal:  Sci Rep       Date:  2016-01-21       Impact factor: 4.379

View more
  2 in total

1.  lncRNA NBAT1 Inhibits Cell Metastasis and Promotes Apoptosis in Endometrial Cancer by Sponging miR-21-5p to Regulate PTEN.

Authors:  Chunhua Tian; Jing Su; Zhao Ma; Yang Wu; Hongyun Ma
Journal:  Comput Math Methods Med       Date:  2022-07-20       Impact factor: 2.809

Review 2.  Non-coding RNAs in skin cancers:Biological roles and molecular mechanisms.

Authors:  Fei Liu; Shenglong Li
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.